Detalle de: GSK-3 Inhibitors: From the Brain to the Retina and Back Again
| Title | GSK-3 Inhibitors: From the Brain to the Retina and Back Again |
| Abstract |
Enzyme glycogen synthase kinase-3 (GSK-3) is a candidate pharmacological target for the treatment of neurodegenerative diseases of the brain. Given the many molecular, cellular, and functional features shared by the brain and the retina in both physiological and pathological processes, drugs originally designed to treat neurodegenerative diseases of the brain could be useful candidates for the treatment of retinal degenerative pathologies. Moreover, the accessibility of the eye to noninvasive, quantitative diagnostic techniques allows for easier evaluation of the efficacy of candidate therapies in clinical trials. In this chapter, we discuss the potential of GSK-3 inhibitors in the treatment of retinal degeneration. |
| Apa Reference | Sánchez-Cruz, A., Martínez, A., de la Rosa, E. J., & Hernández-Sánchez, C. (2019). GSK-3 Inhibitors: From the Brain to the Retina and Back Again. Retinal Degenerative Diseases, 437–441. 10.1007/978-3-030-27378-1_72 |
| Doi | 10.1007/978-3-030-27378-1_72 |
| Publication Date | 2019 |
| Publication Type | Book / chapter |
| Researcher | Ana Martínez |
| Ontology | Drug Discovery and design |
| Research Groups | Translational Medicinal and Biological Chemistry |
| Tools |